See Credit Details Below
Overview
The prospects for healthcare M&A in 2024 are murky at best: 2023 was another challenging year for healthcare M&A. According to a recent report by PWC, global healthcare M&A year over year deal volume declined by 8%. And that followed a difficult 2022, where global healthcare M&A volumes declined by 23% compared with 2021 levels.
Moreover, the factors that contributed to those disappointing results persist: Interest rates remain high, attractive healthcare targets have been coming to market with less frequency, and the environment for regulatory scrutiny has remained intense.
On the other hand, there is also reason for hope. The M&A market at end of 2023 and beginning of 2024 have shown signs of a rebound. In addition, buyers and sellers seem to have adjusted to lower valuations and the current lending environment. Add to that that there is pent up demand among both buyers and sellers and that there is the prospect (or even promise) of interest rate cuts on the horizon and the picture seems to brighten.
But regardless of overall healthcare M&A trends, professionals engaging in M&A need to plan and execute their M&A strategy with thought, preparation, and care.
The following topics will be explored:
- Overview of healthcare M&A trends (10 minutes)
- Social and economic drivers impacting healthcare M&A activity (5 minutes)
- Current trends in healthcare M&A (5 minutes)
- Risk factors and key considerations for buyers (10 minutes)
- Best practices for healthcare M&A due diligence (10 minutes)
- Deal terms considerations for healthcare M&A (10 minutes)
- Healthcare M&A outlook for 2022 and beyond (10 minutes)
Who Should Attend: In-house counsel, outside attorneys, compliance and other allied professionals participating in healthcare M&A transactions
Program Level: Update
Prerequisites: None
Advanced Preparation: None
Faculty:
Joseph Ehrlich
Brown & Brown Risk Solutions
Ahmed Elganzouri
SkinCure Oncology
Ilan Peress
Brown & Brown Risk Solutions